Randox Biosciences release two new oncology biomarkers

Randox Biosciences release two new oncology biomarkers

We are delighted to introduce you to two new oncology biomarkers that we have recently added to our portfolio; IL-18* and M2-PK*.


IL-18 is a proinflammatory cytokine closely related to IL-1α and is believed to play a role in immune surveillance of various tumours. Elevated IL-18 is associated with various tumour types including prostate, lung, bladder and pancreatic cancer, as well as non-malignant conditions affecting the kidneys and bones.

The majority of IL-18 in serum is sequestered as an inactive dimer and only a small proportion is present as the active monomer. Current assays detect only monomeric IL-18. The use of monomeric assays has shown modest increases of this cytokine in cancer patient serum despite the observation that the bulk of IL-18 in serum was in a dimeric form and therefore undetectable by current assays.

Randox has developed an IL-18 RUO Elisa, a new biomarker using in-house antibodies which detects total IL-18 in serum. A clinical application study has shown that this immunoassay has the potential to detect individuals with early stage cancer from those with non-malignant disease.


Randox has also released a new immunoassay detecting M2 Pyruvate Kinase (M2-PK) in serum.   M2-PK is significantly increased in various cancers including colorectal and lung cancer. The assay incorporates novel immunoreagents which are highly specific to the M2-isoform despite the disease-associated M2-PK and the ubiquitous M1-PK isoform only differing by 22 out of 531 amino acids.

For more information, please email us at info@randoxbiosciences.com

Leave a Reply


Be sure to include your first and last name.

If you don't have one, no problem! Just leave this blank.